Which has higher earnings & valuation, SDGR or MANE?

Veradermics has lower revenue, but higher earnings than Schrodinger. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Schrodinger $255.87M 4.17 -$103.26M -$1.41 N/A Veradermics N/A N/A N/A N/A N/A

Does the media favor SDGR or MANE?

In the previous week, Schrodinger and Schrodinger both had 2 articles in the media. Schrodinger's average media sentiment score of 0.93 beat Veradermics' score of 0.54 indicating that Schrodinger is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Schrodinger 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, ERAS or SDGR?

Schrodinger has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Erasca N/A N/A -$124.55M -$0.93 N/A Schrodinger $255.87M 4.17 -$103.26M -$1.41 N/A

Is ERAS or SDGR more profitable?

Erasca has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Schrodinger's return on equity of -30.85% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -35.31% -29.49% Schrodinger -40.61% -30.85% -15.32%

Does the media refer more to ERAS or SDGR?

In the previous week, Erasca had 22 more articles in the media than Schrodinger. MarketBeat recorded 24 mentions for Erasca and 2 mentions for Schrodinger. Schrodinger's average media sentiment score of 0.93 beat Erasca's score of -0.20 indicating that Schrodinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 1 Very Positive mention(s) 1 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 6 Very Negative mention(s) Neutral Schrodinger 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Schrodinger (SDGR) Competitors

$14.45 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$14.36 -0.09 (-0.66%)

As of 06/12/2026 07:40 PM Eastern

Compare

SDGR vs. MANE, EWTX, CPRX, KNSA, and ERAS

Should you buy Schrodinger stock or one of its competitors? MarketBeat compares Schrodinger with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Schrodinger include Veradermics (MANE), Edgewise Therapeutics (EWTX), Catalyst Pharmaceuticals (CPRX), Kiniksa Pharmaceuticals International (KNSA), and Erasca (ERAS). These companies are all part of the "pharmaceutical products" industry.

How does Schrodinger compare to Veradermics?

Schrodinger (NASDAQ:SDGR) and Veradermics (NYSE:MANE) are both pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

Schrodinger currently has a consensus target price of $20.25, indicating a potential upside of 40.14%. Veradermics has a consensus target price of $109.00, indicating a potential upside of 13.65%. Given Schrodinger's higher possible upside, research analysts plainly believe Schrodinger is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Veradermics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Schrodinger and Schrodinger both had 2 articles in the media. Schrodinger's average media sentiment score of 0.93 beat Veradermics' score of 0.54 indicating that Schrodinger is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Schrodinger	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.1% of Schrodinger shares are owned by institutional investors. 10.1% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Veradermics has lower revenue, but higher earnings than Schrodinger.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$255.87M	4.17	-$103.26M	-$1.41	N/A
Veradermics	N/A	N/A	N/A	N/A	N/A

Veradermics has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Veradermics' return on equity of 0.00% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.61%	-30.85%	-15.32%
Veradermics	N/A	N/A	N/A

Summary

Schrodinger and Veradermics tied by winning 5 of the 10 factors compared between the two stocks.

How does Schrodinger compare to Edgewise Therapeutics?

Schrodinger (NASDAQ:SDGR) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Schrodinger has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$255.87M	4.17	-$103.26M	-$1.41	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

In the previous week, Schrodinger had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 2 mentions for Schrodinger and 1 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.89 beat Schrodinger's score of 0.93 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Schrodinger	Positive
Edgewise Therapeutics	Very Positive

79.1% of Schrodinger shares are owned by institutional investors. 10.1% of Schrodinger shares are owned by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Edgewise Therapeutics has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Schrodinger's return on equity of -30.85% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.61%	-30.85%	-15.32%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

Schrodinger presently has a consensus price target of $20.25, indicating a potential upside of 40.14%. Edgewise Therapeutics has a consensus price target of $44.22, indicating a potential upside of 26.97%. Given Schrodinger's higher possible upside, research analysts plainly believe Schrodinger is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Schrodinger has a beta of 1.64, suggesting that its share price is 64% more volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

Summary

Schrodinger beats Edgewise Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Schrodinger compare to Catalyst Pharmaceuticals?

Schrodinger (NASDAQ:SDGR) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Schrodinger currently has a consensus price target of $20.25, suggesting a potential upside of 40.14%. Catalyst Pharmaceuticals has a consensus price target of $32.00, suggesting a potential upside of 2.04%. Given Schrodinger's higher possible upside, analysts clearly believe Schrodinger is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

In the previous week, Schrodinger had 1 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 2 mentions for Schrodinger and 1 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.43 beat Schrodinger's score of 0.93 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Schrodinger	Positive
Catalyst Pharmaceuticals	Positive

79.1% of Schrodinger shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 10.1% of Schrodinger shares are held by insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Schrodinger's net margin of -40.61%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.61%	-30.85%	-15.32%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Catalyst Pharmaceuticals has higher revenue and earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$255.87M	4.17	-$103.26M	-$1.41	N/A
Catalyst Pharmaceuticals	$588.99M	6.52	$214.33M	$1.74	18.02

Schrodinger has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Summary

Catalyst Pharmaceuticals beats Schrodinger on 13 of the 17 factors compared between the two stocks.

How does Schrodinger compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Schrodinger (NASDAQ:SDGR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 79.1% of Schrodinger shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by insiders. Comparatively, 10.1% of Schrodinger shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Kiniksa Pharmaceuticals International had 1 more articles in the media than Schrodinger. MarketBeat recorded 3 mentions for Kiniksa Pharmaceuticals International and 2 mentions for Schrodinger. Kiniksa Pharmaceuticals International's average media sentiment score of 1.18 beat Schrodinger's score of 0.93 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Schrodinger	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International currently has a consensus target price of $60.86, indicating a potential upside of 17.28%. Schrodinger has a consensus target price of $20.25, indicating a potential upside of 40.14%. Given Schrodinger's higher possible upside, analysts plainly believe Schrodinger is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Schrodinger's net margin of -40.61%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Schrodinger	-40.61%	-30.85%	-15.32%

Kiniksa Pharmaceuticals International has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market. Comparatively, Schrodinger has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	5.89	$59.01M	$0.90	57.66
Schrodinger	$255.87M	4.17	-$103.26M	-$1.41	N/A

Summary

Kiniksa Pharmaceuticals International beats Schrodinger on 13 of the 16 factors compared between the two stocks.

How does Schrodinger compare to Erasca?

Erasca (NASDAQ:ERAS) and Schrodinger (NASDAQ:SDGR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

Erasca presently has a consensus price target of $20.11, suggesting a potential upside of 43.14%. Schrodinger has a consensus price target of $20.25, suggesting a potential upside of 40.14%. Given Erasca's stronger consensus rating and higher probable upside, equities analysts clearly believe Erasca is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Erasca has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Schrodinger's return on equity of -30.85% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Schrodinger	-40.61%	-30.85%	-15.32%

Schrodinger has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Schrodinger	$255.87M	4.17	-$103.26M	-$1.41	N/A

Erasca has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, Schrodinger has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market.

67.8% of Erasca shares are held by institutional investors. Comparatively, 79.1% of Schrodinger shares are held by institutional investors. 14.2% of Erasca shares are held by company insiders. Comparatively, 10.1% of Schrodinger shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Erasca had 22 more articles in the media than Schrodinger. MarketBeat recorded 24 mentions for Erasca and 2 mentions for Schrodinger. Schrodinger's average media sentiment score of 0.93 beat Erasca's score of -0.20 indicating that Schrodinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	1 Very Positive mention(s)	1 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	6 Very Negative mention(s)	Neutral
Schrodinger	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Schrodinger beats Erasca on 8 of the 15 factors compared between the two stocks.

Get Schrodinger News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SDGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SDGR vs. The Competition

Export

Metric	Schrodinger	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.07B	$1.50B	$6.53B	$12.05B
Dividend Yield	N/A	N/A	2.67%	5.66%
P/E Ratio	-10.25	77.55	23.99	24.42
Price / Sales	4.17	6.96	511.38	110.47
Price / Cash	N/A	22.98	27.48	37.92
Price / Book	2.93	4.82	10.65	6.82
Net Income	-$103.26M	-$54.76M	$3.57B	$337.56M
7 Day Performance	0.35%	-1.67%	0.58%	1.17%
1 Month Performance	20.92%	0.13%	1.54%	3.16%
1 Year Performance	-32.57%	-6.47%	25.40%	30.58%

Schrodinger Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SDGR Schrodinger	2.7689 of 5 stars	$14.45 flat	$20.25 +40.1%	-32.6%	$1.07B	$255.87M	N/A	790	Positive News
MANE Veradermics	N/A	$90.74 -1.0%	$109.00 +20.1%	N/A	$3.83B	N/A	N/A	19	Analyst Upgrade Gap Up
EWTX Edgewise Therapeutics	2.9387 of 5 stars	$34.84 -2.1%	$44.22 +26.9%	+127.8%	$3.83B	N/A	N/A	60
CPRX Catalyst Pharmaceuticals	3.6737 of 5 stars	$31.28 +0.0%	$32.00 +2.3%	+33.3%	$3.83B	$588.99M	17.98	80	Positive News
KNSA Kiniksa Pharmaceuticals International	4.1227 of 5 stars	$49.04 +1.3%	$60.86 +24.1%	+83.4%	$3.73B	$677.56M	54.49	220	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SDGR) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Schrodinger (SDGR) Competitors

SDGR vs. MANE, EWTX, CPRX, KNSA, and ERAS

How does Schrodinger compare to Veradermics?

Summary

How does Schrodinger compare to Edgewise Therapeutics?

Summary

How does Schrodinger compare to Catalyst Pharmaceuticals?

Summary

How does Schrodinger compare to Kiniksa Pharmaceuticals International?

Summary

How does Schrodinger compare to Erasca?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SDGR vs. The Competition

Schrodinger Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Schrodinger (SDGR) Competitors

SDGR vs. MANE, EWTX, CPRX, KNSA, and ERAS

How does Schrodinger compare to Veradermics?

Do analysts rate SDGR or MANE?

Does the media favor SDGR or MANE?

Do institutionals and insiders believe in SDGR or MANE?

Which has higher earnings & valuation, SDGR or MANE?

Is SDGR or MANE more profitable?

Summary

How does Schrodinger compare to Edgewise Therapeutics?

Which has higher valuation and earnings, SDGR or EWTX?

Does the media prefer SDGR or EWTX?

Do insiders & institutionals have more ownership in SDGR or EWTX?

Is SDGR or EWTX more profitable?

Do analysts rate SDGR or EWTX?

Which has more volatility and risk, SDGR or EWTX?

Summary

How does Schrodinger compare to Catalyst Pharmaceuticals?

Do analysts recommend SDGR or CPRX?

Does the media prefer SDGR or CPRX?

Do insiders and institutionals hold more shares of SDGR or CPRX?

Is SDGR or CPRX more profitable?

Which has preferable valuation and earnings, SDGR or CPRX?

Which has more risk and volatility, SDGR or CPRX?

Summary

How does Schrodinger compare to Kiniksa Pharmaceuticals International?

Do insiders and institutionals believe in KNSA or SDGR?

Does the media refer more to KNSA or SDGR?

Do analysts recommend KNSA or SDGR?

Is KNSA or SDGR more profitable?

Which has more volatility & risk, KNSA or SDGR?

Which has stronger valuation and earnings, KNSA or SDGR?

Summary

How does Schrodinger compare to Erasca?

Do analysts rate ERAS or SDGR?

Is ERAS or SDGR more profitable?

Which has higher earnings and valuation, ERAS or SDGR?

Which has more volatility and risk, ERAS or SDGR?

Do insiders and institutionals have more ownership in ERAS or SDGR?

Does the media refer more to ERAS or SDGR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SDGR vs. The Competition

Schrodinger Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools